MarketPulse

PKM2 modulator

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Sitryx's First-in-Class PKM2 Drug Clears Phase 1a, Eyes Atopic Dermatitis Market

Sitryx Therapeutics reports positive Phase 1a data for SYX-5219, a first-in-class oral PKM2 modulator showing safety and immunomodulation signals in atopic dermatitis development.
LLYGSKoral therapyclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Sitryx to Showcase Autoimmune Pipeline at Four Major Biopharma Conferences in April

Clinical-stage biotech Sitryx Therapeutics will present at four investor conferences in April 2026, highlighting its oral autoimmune and inflammatory disease therapies.
LLYGSKoral therapyinvestor conference